Cardiopulmonary Bypass Equipment Market Insights, Competitive Landscape and Market Forecast–2026
This report can be delivered to the clients within 7-10 Business Days
CARDIOPULMONARY BYPASS EQUIPMENT MARKET BY PRODUCT (HEART–LUNG MACHINES, OXYGENATORS, AUTOTRANSFUSION SYSTEMS, AND OTHERS), BY APPLICATION (CARDIOVASCULAR, RESPIRATORY, HEMODIALYSIS, AND OTHERS), BY END-USER (HOSPITALS, SPECIALTY CLINICS, DIALYSIS CENTERS, AND AMBULATORY SURGERY CENTERS), BY GEOGRAPHY IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES AND RISING GERIATRIC POPULATION
Global Cardiopulmonary Bypass Equipment Market was valued at USD 389.14 million in 2020, growing at a CAGR of 4.13% during the forecast period from 2021 to 2026, to reach USD 713.24 million by 2026. The demand for Cardiopulmonary Bypass Equipment is primarily motivated by the increase in the prevalence of cardiovascular diseases like atrial fibrillation, atrial flutter and supraventricular tachycardia, decrease in heart muscle elasticity, decrease in heart output, rising burden of cardiovascular diseases, and rising geriatric population.
CARDIOPULMONARY BYPASS EQUIPMENT MARKET DYNAMICS:
According to World Health Organization (2021), approximately 17.9 million people die from cardiovascular diseases, which is an estimated 31% of all deaths worldwide. By 2030, around 23.6 million people are expected to die due to cardiovascular disorders. Thus, the number of surgeries for cardiovascular diseases are increasing, requiring cardiopulmonary bypass (CPB), which provides a bloodless field for cardiac surgery. The advancement in cardiac surgery have been possible due to the development of cardiopulmonary bypass.
Heart disease is the leading cause of death among men and women in the US accounting for about 1 in every 4 deaths. According to the Centers for Disease Control and Prevention (CDC), more than 795,000 people in the United States suffer from a stroke every year. Coronary heart disease is the most common type of heart disease, killing over 370,000 people each year. Coronary heart disease occurs when arteries around the heart become blocked or occluded, in most cases by plaque. Approximately 200,000 coronary artery bypass graft surgeries take place each year in the US and are the most commonly performed cardiac procedure. Henceforth, it require the Cardiopulmonary Bypass Equipment, such as heart-lung machines and oxygenators.
Moreover, the companies are increasing their research and development to develop the products which have better efficacy and are easy to operate. The COVID-19 has boosted the demand for compact cardiopulmonary bypass system and in October 2020, Abiomed announced that its compact cardiopulmonary bypass system, Breethe OXY-1, received 510(k) clearance from the FDA. The technology will support new patient populations, such as COVID-19 patients and others who need lung support. Therefore, such initiative from companies and regulatory authorities are expected to help the market and the patients in their treatment which will drive the market growth also.
As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure of such patients is expected to double and reach 1.5 billion by 2050. Thus, all these factors are projected to drive the growth of the market for Cardiopulmonary Bypass Equipment.
Certain factors such as the Cardiopulmonary Bypass Equipment requiring trained professionals to operate, product getting recalled, and complications during surgery pose as a minor hurdle for the growth of the market.
CARDIOPULMONARY BYPASS EQUIPMENT SEGMENT ANALYSIS:
By Product (Heart–Lung Machines, Oxygenators, Autotransfusion Systems, and Others), By Application (Cardiovascular, Respiratory, Hemodialysis, and Others), By End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In type of devices segment, heart–lung machines is expected to hold a largest share in the market as cardiopulmonary bypass equipment. It is an important tool required during any cardiopulmonary surgery. An artificial heart-lung machine is used in open heart surgeries to support the proper functioning of the heart and body during the surgery. The heart-lung machine consists of a chamber that receives blood from the body, oxygenates the blood, and transfers it to all parts of the body. This machine is connected to the patient with a series of tubes, which is removed after the completion of the surgery when the heart and lungs resume its functions.
The heart–lung machines market is driven by the factors, such as the increase in the prevalence of heart disease, a growing aging population who are very susceptible to coronary heart disease and pulmonary diseases, technological developments in artificially managing the organs that minimize burden on heart and lungs during surgery, and improved efficiency of devices.
Additionally, assistance from government bodies, in equipping new/existing hospitals and healthcare centers in rural regions, is expected to enhance the market potential in several countries. Hence, all the above mentioned factors is expected to drive the segment growth.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL CARDIOPULMONARY BYPASS EQUIPMENT MARKET:
North America is expected to dominate the overall Cardiopulmonary Bypass Equipment market during the forecast period. This domination is due to the growing number of surgeries, and demand for advance technologies in cardiopulmonary bypass equipment, and others is driving the regional growth.
Further, In the United States, the risk of being affected by a cardiopulmonary disease is increasing dramatically due to the changing lifestyle and rising geriatric population. This indicates that most Americans are likely to be affected by chronic disease, in the coming decades. This situation is giving rise to a critical need for Cardiopulmonary Bypass Equipment for the diagnosis, prevention, and treatment of chronic disease.
According to the Centers for Disease Control and Prevention (CDC), every year in the US, over 800,000 people die from heart disease, accounting for 1 in every 3 deaths and around 160,000 are under the age of 65. By 2035, in the US alone, the economic burden of coronary artery disease (CAD) will increase to USD 749 billion, which in turns, will increase the demand for Cardiopulmonary Bypass Equipment.
Europe and Asia-Pacific region has the future potential growth for the Global Cardiopulmonary Bypass Equipment. This is due to the rising burden of cardiovascular diseases in the European region countries and in Asia countries also. The increasing prevalence of chronic cardiovascular diseases and greater adoption of advanced devices is likely to augment the market during the forecast period. The devices in Asian countries are priced at a substantially lower rate compared to the international markets such as the United States because of the support from the government bodies. Such an established regulatory scenario for these devices is expected to boost the expansion of the market in Asia Pacific during the forecast period.
CARDIOPULMONARY BYPASS EQUIPMENT KEY PLAYERS:
Some of the key market players operating in the Cardiopulmonary Bypass Equipment market includes Medtronic PLC, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica Ltda, Tianjin Medical, Senko Medical Instrument Manufacturing Co. Ltd., and others.
RECENT DEVELOPMENTAL ACTIVITIES IN CARDIOPULMONARY BYPASS EQUIPMENT:
? In August 2021, FDA awarded the breakthrough privileges to Abiomed's Impella ECP expandable percutaneous heart pump.
? In April 2021, LivaNova received FDA 510(k) clearance for its B-Capta system integrated into the S5 heart-lung machine.
? In October 2020, Abiomed received FDA 510(k) clearance for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.
KEY TAKES AWAY FROM THE CARDIOPULMONARY BYPASS EQUIPMENT MARKET REPORT STUDY
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Cardiopulmonary Bypass Equipment Market.
? Various opportunities available for the other competitor in the Cardiopulmonary Bypass Equipment Market space.
? What are the top performing segments in 2020? How these segments will perform in 2026.
? Which is the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS CARDIOPULMONARY BYPASS EQUIPMENT MARKET REPORT STUDY
? Cardiopulmonary Bypass Equipment providers
? Research organizations and consulting companies
? Cardiopulmonary Bypass Equipment-related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders
? Various End-users who want to know more about the Cardiopulmonary Bypass Equipment Market and latest technological developments in the Cardiopulmonary Bypass Equipment market.
FREQUENTLY ASKED QUESTIONS FOR CARDIOPULMONARY BYPASS EQUIPMENT MARKET:
What is Cardiopulmonary Bypass Equipment?
Cardiopulmonary bypass (CPB), also known as heart-lung machine, provides a bloodless field for cardiac surgery, and do the work of both the heart (i.e., pumps blood) and the lungs (i.e., oxygenates the blood). CPB circuit includes pumps, cannulae, tubing, reservoir, oxygenator, heat exchanger and arterial line filter. Cardiopulmonary bypass machines are operated by perfusionists to bypass the heart and lungs during open heart surgery.
What is the market for Global Cardiopulmonary Bypass Equipment?
Global Cardiopulmonary Bypass Equipment Market was valued at USD 389.14 million in 2020, growing at a CAGR of 4.13% during the forecast period from 2021 to 2026, to reach USD 713.24 million by 2026.
What are the drivers for Cardiopulmonary Bypass Equipment Market?
The major drivers driving the demand for Cardiopulmonary Bypass Equipment are the increase in the prevalence of cardiovascular diseases like atrial fibrillation, atrial flutter and supraventricular tachycardia, decrease in heart muscle elasticity, decrease in heart output, rising burden of cardiovascular diseases, and rising geriatric population.
What are the key players operating in Global Cardiopulmonary Bypass Equipment Market?
Some of the key market players operating in the Cardiopulmonary Bypass Equipment market includes Medtronic PLC, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica Ltda, Tianjin Medical, Senko Medical Instrument Manufacturing Co. Ltd., and others.
What regions has the highest share in Cardiopulmonary Bypass Equipment Market?
North America is expected to dominate the overall Cardiopulmonary Bypass Equipment Market during the forecast period, 2021 to 2026. This domination is due to the g the growing number of surgeries, demand for advance technologies in cardiopulmonary bypass equipment and rise in healthcare expenditure by the US government.
CARDIOPULMONARY BYPASS EQUIPMENT MARKET BY PRODUCT (HEART–LUNG MACHINES, OXYGENATORS, AUTOTRANSFUSION SYSTEMS, AND OTHERS), BY APPLICATION (CARDIOVASCULAR, RESPIRATORY, HEMODIALYSIS, AND OTHERS), BY END-USER (HOSPITALS, SPECIALTY CLINICS, DIALYSIS CENTERS, AND AMBULATORY SURGERY CENTERS), BY GEOGRAPHY IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES AND RISING GERIATRIC POPULATION
Global Cardiopulmonary Bypass Equipment Market was valued at USD 389.14 million in 2020, growing at a CAGR of 4.13% during the forecast period from 2021 to 2026, to reach USD 713.24 million by 2026. The demand for Cardiopulmonary Bypass Equipment is primarily motivated by the increase in the prevalence of cardiovascular diseases like atrial fibrillation, atrial flutter and supraventricular tachycardia, decrease in heart muscle elasticity, decrease in heart output, rising burden of cardiovascular diseases, and rising geriatric population.
CARDIOPULMONARY BYPASS EQUIPMENT MARKET DYNAMICS:
According to World Health Organization (2021), approximately 17.9 million people die from cardiovascular diseases, which is an estimated 31% of all deaths worldwide. By 2030, around 23.6 million people are expected to die due to cardiovascular disorders. Thus, the number of surgeries for cardiovascular diseases are increasing, requiring cardiopulmonary bypass (CPB), which provides a bloodless field for cardiac surgery. The advancement in cardiac surgery have been possible due to the development of cardiopulmonary bypass.
Heart disease is the leading cause of death among men and women in the US accounting for about 1 in every 4 deaths. According to the Centers for Disease Control and Prevention (CDC), more than 795,000 people in the United States suffer from a stroke every year. Coronary heart disease is the most common type of heart disease, killing over 370,000 people each year. Coronary heart disease occurs when arteries around the heart become blocked or occluded, in most cases by plaque. Approximately 200,000 coronary artery bypass graft surgeries take place each year in the US and are the most commonly performed cardiac procedure. Henceforth, it require the Cardiopulmonary Bypass Equipment, such as heart-lung machines and oxygenators.
Moreover, the companies are increasing their research and development to develop the products which have better efficacy and are easy to operate. The COVID-19 has boosted the demand for compact cardiopulmonary bypass system and in October 2020, Abiomed announced that its compact cardiopulmonary bypass system, Breethe OXY-1, received 510(k) clearance from the FDA. The technology will support new patient populations, such as COVID-19 patients and others who need lung support. Therefore, such initiative from companies and regulatory authorities are expected to help the market and the patients in their treatment which will drive the market growth also.
As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure of such patients is expected to double and reach 1.5 billion by 2050. Thus, all these factors are projected to drive the growth of the market for Cardiopulmonary Bypass Equipment.
Certain factors such as the Cardiopulmonary Bypass Equipment requiring trained professionals to operate, product getting recalled, and complications during surgery pose as a minor hurdle for the growth of the market.
CARDIOPULMONARY BYPASS EQUIPMENT SEGMENT ANALYSIS:
By Product (Heart–Lung Machines, Oxygenators, Autotransfusion Systems, and Others), By Application (Cardiovascular, Respiratory, Hemodialysis, and Others), By End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In type of devices segment, heart–lung machines is expected to hold a largest share in the market as cardiopulmonary bypass equipment. It is an important tool required during any cardiopulmonary surgery. An artificial heart-lung machine is used in open heart surgeries to support the proper functioning of the heart and body during the surgery. The heart-lung machine consists of a chamber that receives blood from the body, oxygenates the blood, and transfers it to all parts of the body. This machine is connected to the patient with a series of tubes, which is removed after the completion of the surgery when the heart and lungs resume its functions.
The heart–lung machines market is driven by the factors, such as the increase in the prevalence of heart disease, a growing aging population who are very susceptible to coronary heart disease and pulmonary diseases, technological developments in artificially managing the organs that minimize burden on heart and lungs during surgery, and improved efficiency of devices.
Additionally, assistance from government bodies, in equipping new/existing hospitals and healthcare centers in rural regions, is expected to enhance the market potential in several countries. Hence, all the above mentioned factors is expected to drive the segment growth.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL CARDIOPULMONARY BYPASS EQUIPMENT MARKET:
North America is expected to dominate the overall Cardiopulmonary Bypass Equipment market during the forecast period. This domination is due to the growing number of surgeries, and demand for advance technologies in cardiopulmonary bypass equipment, and others is driving the regional growth.
Further, In the United States, the risk of being affected by a cardiopulmonary disease is increasing dramatically due to the changing lifestyle and rising geriatric population. This indicates that most Americans are likely to be affected by chronic disease, in the coming decades. This situation is giving rise to a critical need for Cardiopulmonary Bypass Equipment for the diagnosis, prevention, and treatment of chronic disease.
According to the Centers for Disease Control and Prevention (CDC), every year in the US, over 800,000 people die from heart disease, accounting for 1 in every 3 deaths and around 160,000 are under the age of 65. By 2035, in the US alone, the economic burden of coronary artery disease (CAD) will increase to USD 749 billion, which in turns, will increase the demand for Cardiopulmonary Bypass Equipment.
Europe and Asia-Pacific region has the future potential growth for the Global Cardiopulmonary Bypass Equipment. This is due to the rising burden of cardiovascular diseases in the European region countries and in Asia countries also. The increasing prevalence of chronic cardiovascular diseases and greater adoption of advanced devices is likely to augment the market during the forecast period. The devices in Asian countries are priced at a substantially lower rate compared to the international markets such as the United States because of the support from the government bodies. Such an established regulatory scenario for these devices is expected to boost the expansion of the market in Asia Pacific during the forecast period.
CARDIOPULMONARY BYPASS EQUIPMENT KEY PLAYERS:
Some of the key market players operating in the Cardiopulmonary Bypass Equipment market includes Medtronic PLC, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica Ltda, Tianjin Medical, Senko Medical Instrument Manufacturing Co. Ltd., and others.
RECENT DEVELOPMENTAL ACTIVITIES IN CARDIOPULMONARY BYPASS EQUIPMENT:
? In August 2021, FDA awarded the breakthrough privileges to Abiomed's Impella ECP expandable percutaneous heart pump.
? In April 2021, LivaNova received FDA 510(k) clearance for its B-Capta system integrated into the S5 heart-lung machine.
? In October 2020, Abiomed received FDA 510(k) clearance for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.
KEY TAKES AWAY FROM THE CARDIOPULMONARY BYPASS EQUIPMENT MARKET REPORT STUDY
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Cardiopulmonary Bypass Equipment Market.
? Various opportunities available for the other competitor in the Cardiopulmonary Bypass Equipment Market space.
? What are the top performing segments in 2020? How these segments will perform in 2026.
? Which is the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS CARDIOPULMONARY BYPASS EQUIPMENT MARKET REPORT STUDY
? Cardiopulmonary Bypass Equipment providers
? Research organizations and consulting companies
? Cardiopulmonary Bypass Equipment-related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders
? Various End-users who want to know more about the Cardiopulmonary Bypass Equipment Market and latest technological developments in the Cardiopulmonary Bypass Equipment market.
FREQUENTLY ASKED QUESTIONS FOR CARDIOPULMONARY BYPASS EQUIPMENT MARKET:
What is Cardiopulmonary Bypass Equipment?
Cardiopulmonary bypass (CPB), also known as heart-lung machine, provides a bloodless field for cardiac surgery, and do the work of both the heart (i.e., pumps blood) and the lungs (i.e., oxygenates the blood). CPB circuit includes pumps, cannulae, tubing, reservoir, oxygenator, heat exchanger and arterial line filter. Cardiopulmonary bypass machines are operated by perfusionists to bypass the heart and lungs during open heart surgery.
What is the market for Global Cardiopulmonary Bypass Equipment?
Global Cardiopulmonary Bypass Equipment Market was valued at USD 389.14 million in 2020, growing at a CAGR of 4.13% during the forecast period from 2021 to 2026, to reach USD 713.24 million by 2026.
What are the drivers for Cardiopulmonary Bypass Equipment Market?
The major drivers driving the demand for Cardiopulmonary Bypass Equipment are the increase in the prevalence of cardiovascular diseases like atrial fibrillation, atrial flutter and supraventricular tachycardia, decrease in heart muscle elasticity, decrease in heart output, rising burden of cardiovascular diseases, and rising geriatric population.
What are the key players operating in Global Cardiopulmonary Bypass Equipment Market?
Some of the key market players operating in the Cardiopulmonary Bypass Equipment market includes Medtronic PLC, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica Ltda, Tianjin Medical, Senko Medical Instrument Manufacturing Co. Ltd., and others.
What regions has the highest share in Cardiopulmonary Bypass Equipment Market?
North America is expected to dominate the overall Cardiopulmonary Bypass Equipment Market during the forecast period, 2021 to 2026. This domination is due to the g the growing number of surgeries, demand for advance technologies in cardiopulmonary bypass equipment and rise in healthcare expenditure by the US government.
1. CARDIOPULMONARY BYPASS EQUIPMENT MARKET REPORT INTRODUCTION
2. CARDIOPULMONARY BYPASS EQUIPMENT EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4. CARDIOPULMONARY BYPASS EQUIPMENT MARKET KEY FACTORS ANALYSIS
4.1 Cardiopulmonary Bypass Equipment Market Drivers
4.1.1 Increase in the prevalence of cardiovascular diseases and respiratory diseases
4.1.2 Increasing number of surgical procedures
4.1.3 Rising burden of cardiovascular diseases
4.1.4 Rising geriatric population
4.2 Cardiopulmonary Bypass Equipment Market Restraints and Challenges
4.2.1 High cost of cardiac surgery and risk of failure during the surgery
4.2.2 Strict regulations by regulatory bodies
4.3 Cardiopulmonary Bypass Equipment Market Opportunities
4.3.1 Growing demand for minimal invasive surgery
4.3.2 Growing demand for Cardiopulmonary Bypass Equipment in non-hospital settings
5. CARDIOPULMONARY BYPASS EQUIPMENT PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON CARDIOPULMONARY BYPASS EQUIPMENT MARKET
7. CARDIOPULMONARY BYPASS EQUIPMENT MARKET LAYOUT
7.1 By Product
7.1.1 Heart–Lung Machines
7.1.2 Oxygenators
7.1.3 Autotransfusion Systems
7.1.4 Others
7.2 By Application
7.2.1 Cardiovascular
7.2.2 Respiratory
7.2.3 Hemodialysis
7.2.4 Others
7.3 By End-User
7.2.1 Hospitals
7.2.2 Specialty Clinics
7.2.3 Dialysis Centers
7.2.4 Ambulatory Surgery Centers
7.4 By Geography
7.4.1 North America
7.4.1.1 North America Cardiopulmonary Bypass Equipment Market, by Product
7.4.1.2 North America Cardiopulmonary Bypass Equipment Market, by Application
7.4.1.3 North America Cardiopulmonary Bypass Equipment Market, by End-User
7.4.1.4 North America Cardiopulmonary Bypass Equipment Market, by Country
7.4.1.4.1 United States
7.4.1.4.2 Canada
7.4.1.4.3 Mexico
7.4.2 Europe
7.4.2.1 Europe Cardiopulmonary Bypass Equipment Market, by Product
7.4.2.2 Europe Cardiopulmonary Bypass Equipment Market, by Application
7.4.2.3 Europe Cardiopulmonary Bypass Equipment Market, by End-User
7.4.2.4 Europe Cardiopulmonary Bypass Equipment Market, by Country
7.4.2.4.1 France
7.4.2.4.2 Germany
7.4.2.4.3 United Kingdom
7.4.2.4.4 Italy
7.4.2.4.5 Spain
7.4.2.4.6 Russia
7.4.2.4.7 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Product
7.4.3.2 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Application
7.4.3.3 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by End-User
7.4.3.4 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Country
7.4.3.4.1 China
7.4.3.4.2 Japan
7.4.3.4.3 India
7.4.3.4.4 Australia
7.4.3.4.5 South Korea
7.4.3.4.6 Rest of Asia Pacific
7.4.4 Rest of the World (RoW)
7.4.4.1 RoW Cardiopulmonary Bypass Equipment Market, by Product
7.4.4.2 RoW Cardiopulmonary Bypass Equipment Market, by Application
7.4.4.3 RoW Cardiopulmonary Bypass Equipment Market, by End-User
7.4.4.4 RoW Cardiopulmonary Bypass Equipment Market, by Region
7.4.4.4.1 Middle East
7.4.4.4.2 Africa
7.4.4.4.3 South America
8. CARDIOPULMONARY BYPASS EQUIPMENT GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. CARDIOPULMONARY BYPASS EQUIPMENT COMPANY AND PRODUCT PROFILES
9.1 Medtronic Plc
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 LivaNova PLC
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 MAQUET Holding B.V. & Co. KG.
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 ABIOMED
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 Braile Biomedica Ltda
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Tianjin Medical
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Terumo Corp
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Senko Medical Instrument Manufacturing Co.,Ltd.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 Technowood Corp
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 Sorin
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 MicroPort Scientific Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Xenios AG
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Nipro Corporation
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 OriGen Biomedical
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Thoratec Corporation
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
2. CARDIOPULMONARY BYPASS EQUIPMENT EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4. CARDIOPULMONARY BYPASS EQUIPMENT MARKET KEY FACTORS ANALYSIS
4.1 Cardiopulmonary Bypass Equipment Market Drivers
4.1.1 Increase in the prevalence of cardiovascular diseases and respiratory diseases
4.1.2 Increasing number of surgical procedures
4.1.3 Rising burden of cardiovascular diseases
4.1.4 Rising geriatric population
4.2 Cardiopulmonary Bypass Equipment Market Restraints and Challenges
4.2.1 High cost of cardiac surgery and risk of failure during the surgery
4.2.2 Strict regulations by regulatory bodies
4.3 Cardiopulmonary Bypass Equipment Market Opportunities
4.3.1 Growing demand for minimal invasive surgery
4.3.2 Growing demand for Cardiopulmonary Bypass Equipment in non-hospital settings
5. CARDIOPULMONARY BYPASS EQUIPMENT PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON CARDIOPULMONARY BYPASS EQUIPMENT MARKET
7. CARDIOPULMONARY BYPASS EQUIPMENT MARKET LAYOUT
7.1 By Product
7.1.1 Heart–Lung Machines
7.1.2 Oxygenators
7.1.3 Autotransfusion Systems
7.1.4 Others
7.2 By Application
7.2.1 Cardiovascular
7.2.2 Respiratory
7.2.3 Hemodialysis
7.2.4 Others
7.3 By End-User
7.2.1 Hospitals
7.2.2 Specialty Clinics
7.2.3 Dialysis Centers
7.2.4 Ambulatory Surgery Centers
7.4 By Geography
7.4.1 North America
7.4.1.1 North America Cardiopulmonary Bypass Equipment Market, by Product
7.4.1.2 North America Cardiopulmonary Bypass Equipment Market, by Application
7.4.1.3 North America Cardiopulmonary Bypass Equipment Market, by End-User
7.4.1.4 North America Cardiopulmonary Bypass Equipment Market, by Country
7.4.1.4.1 United States
7.4.1.4.2 Canada
7.4.1.4.3 Mexico
7.4.2 Europe
7.4.2.1 Europe Cardiopulmonary Bypass Equipment Market, by Product
7.4.2.2 Europe Cardiopulmonary Bypass Equipment Market, by Application
7.4.2.3 Europe Cardiopulmonary Bypass Equipment Market, by End-User
7.4.2.4 Europe Cardiopulmonary Bypass Equipment Market, by Country
7.4.2.4.1 France
7.4.2.4.2 Germany
7.4.2.4.3 United Kingdom
7.4.2.4.4 Italy
7.4.2.4.5 Spain
7.4.2.4.6 Russia
7.4.2.4.7 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Product
7.4.3.2 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Application
7.4.3.3 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by End-User
7.4.3.4 Asia-Pacific Cardiopulmonary Bypass Equipment Market, by Country
7.4.3.4.1 China
7.4.3.4.2 Japan
7.4.3.4.3 India
7.4.3.4.4 Australia
7.4.3.4.5 South Korea
7.4.3.4.6 Rest of Asia Pacific
7.4.4 Rest of the World (RoW)
7.4.4.1 RoW Cardiopulmonary Bypass Equipment Market, by Product
7.4.4.2 RoW Cardiopulmonary Bypass Equipment Market, by Application
7.4.4.3 RoW Cardiopulmonary Bypass Equipment Market, by End-User
7.4.4.4 RoW Cardiopulmonary Bypass Equipment Market, by Region
7.4.4.4.1 Middle East
7.4.4.4.2 Africa
7.4.4.4.3 South America
8. CARDIOPULMONARY BYPASS EQUIPMENT GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. CARDIOPULMONARY BYPASS EQUIPMENT COMPANY AND PRODUCT PROFILES
9.1 Medtronic Plc
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 LivaNova PLC
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 MAQUET Holding B.V. & Co. KG.
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 ABIOMED
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 Braile Biomedica Ltda
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Tianjin Medical
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Terumo Corp
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Senko Medical Instrument Manufacturing Co.,Ltd.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 Technowood Corp
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 Sorin
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 MicroPort Scientific Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Xenios AG
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Nipro Corporation
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 OriGen Biomedical
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Thoratec Corporation
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
